NYSE: CXCemex Sab De CV Stock
$9.54+0.16 (+1.71%)
Updated Sep 15, 2025
CX Price
$9.54
Fair Value Price
N/A
Market Cap
$13.84B
52 Week Low
$4.89
52 Week High
$9.55
P/E
43.96x
P/B
1.14x
P/S
0.5x
PEG
0.93x
Dividend Yield
0.43%
Revenue
$16.20B
Earnings
$939.00M
Gross Margin
33.6%
Operating Margin
9.64%
Profit Margin
5.8%
Debt to Equity
1.22
Operating Cash Flow
$2B
Beta
1.27
Next Earnings
Oct 28, 2025
Ex-Dividend
Sep 17, 2025
Next Dividend
Sep 25, 2025
CX Overview
CEMEX S.A.B. de C.V., known as Cemex, manufactures and distributes cement, ready-mix concrete, aggregates, and other building supplies through a network of 2,000 retail stores. The company was founded in 1906 and is headquartered in San Pedro, Mexico.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CX's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Building Material
Industry Rating
D
CX
Ranked#1 of 14
Ranked#1 of 14
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $41.78 | C | |
| $129.66 | C | |
| $71.49 | C |
Be the first to know about important CX news, forecast changes, insider trades & much more!
CX News
Overview
Due Diligence Score
–
Industry Average (34)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CX scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CX ($9.54) is trading above its intrinsic value of $5.18, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CX is poor value based on its earnings relative to its share price (43.96x), compared to the US market average (37.32x)
P/E vs Market Valuation
CX is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more CX due diligence checks available for Premium users.
Valuation
CX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
43.96x
Industry
25.92x
Market
37.32x
CX is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
CX is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
CX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.14x
Industry
3.07x
CX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CX price to earnings growth (PEG)
For valuing profitable companies with growth potential
CX is good value based... subscribe to Premium to read more.
PEG Value Valuation
CX's financial health
Profit margin
Revenue
$16.2B
Net Income
$939.0M
Profit Margin
5.8%
CX's Earnings (EBIT) of $1.56B... subscribe to Premium to read more.
Interest Coverage Financials
CX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$27.3B
Liabilities
$14.8B
Debt to equity
1.22
CX's short-term liabilities ($6.09B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CX's long-term liabilities ($8.73B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$1.9B
Investing
-$328.0M
Financing
-$1.3B
CX's operating cash flow ($1.89B)... subscribe to Premium to read more.
Debt Coverage Financials
CX vs Building Material Stocks
Cemex Sab De CV Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.